Engineering Bacteria for Cancer Immunotherapy by Inhibiting IDO Activity and Reprogramming CD8+ T Cell Response
Synthetic Biology in Cancer Immunotherapy: Engineering Bacteria to Inhibit IDO Activity and Reprogram CD8+ T Cell Responses Academic Background In recent years, significant progress has been made in cancer immunotherapy, particularly through the activation of T cells to combat tumors. However, metabolic adaptations in the tumor microenvironment (TM...